Neurotech International Ltd’s Post

Epilepsy is a neurological condition, often complex to diagnose and treat. For critically ill infants in the NICU, PICU, and CVICU, timely and accurate diagnosis of epilepsy is critical for effective treatment and care. Research shows that WGS/WES provides higher diagnostic yields compared to other methods, particularly for early-onset epilepsy and specific clinical features, providing substantial benefits for children aged 2-3 years. Baylor Genetics' WES and WGS offerings aim to end the diagnostic odyssey for patients with unexplained epilepsy, enabling informed patient care. Want to learn more: https://bit.ly/4bWsOCt #ThinkBG #BGreat #Epilepsy

Our fourth Angelman Syndrome Therapeutics Bulletin is out 🧑🔬🧬🔬 What is it? It’s a concise summary about clinical trials, Natural History Study and other key FAST UK activities. You will find the latest published update from The HALOS trial by IONIS….and much more. Please share it with your GP, neurologist, other key medical professionals and carers supporting your child, your child’s school, relatives and friends. You can download your copy by using the link in bio or below: https://lnkd.in/e3RKnDuS Share it as wide as you can 🤗 Please let us know what you think and if there is anything else we can include in the next issue. #cureangelmannow #angelmansyndromeawareness #angelmansyndrome #fastuk #science #naturalhistorystudy #clinicaltrials #AngelmanSyndromeTherapeuticsBulletin #gp #neurologist #paediatrics

🧠 🧸Neuro SPARK, first scoring system specifically developed, using ELSO Registry, #machinelearning methodologies & clinical expertise, to assess risk of neurologic injury in pediatric & neonatal patients on #ECMO: 🧠 predictor variables identified, which demonstrated moderate accuracy in predicting neurologic injury and good calibration 🧠 high/low-risk groups identified, that may aid in targeted neuromonitoring and guide future research 🧠 separate models developed for VV & VA due to their different risk factors and prevalence of neuro-injury ASAIO Journal #PedsICU 🖇️ https://bit.ly/3TGRGaN

Watch a video from the Journal of Neuroscience Nursing Editor, DaiWai Olson, on Early Mobilization of Acute Ischemic Stroke Patients https://lnkd.in/d4GkTRS9 Read the article in the #JNN at https://lnkd.in/dT_aednT #neuronurses #neuronerds #strokenurses

Sobering study: Some severe TBI patients who died after life support withdrawal may have lived with continued care. 🗞 Intensive care units, with or without a consulting neurologist, currently evaluate these patients for their likelihood of recovery. However, this study throws a harsh light on the limitations of today's neuro-prognostication methods. 💡🧠 In my comments to Medscape, I emphasized how research investment in data-driven prediction models could revolutionize our prognostic capabilities, ensuring no patient is prematurely denied their shot at recovery based on flawed assumptions. 🏥 📚 Read more: https://lnkd.in/eW5gmmDd #PrecisionMedicine #BrainInjury #TBI

Our latest paper presents the current evidence for conservative interventions for urinary incontinence in neurological patients International Continence Society (ICS)

Syringomyelia is a rare but significant condition that poses unique challenges within the realm of neurological disorders. Uncover the mysteries of this rare spinal condition and gain deeper insights into its challenges and symptoms in our latest blog post - https://ow.ly/r1M350QmX1h. #SyringomyeliaAwareness #SpinalCordAnatomy #MedicalEducation #SpinalCordInjuries #RareMedicalConditions #FreeOnlineCourses #Alison #EmpowerYourself Saqib Mansoor

Children 4 years and older with uncontrolled seizures could experience developmental limitations that impact cognitive and social function. Poorly controlled seizures have serious cognitive consequences in the developing brain. The sooner you act to control seizures, the more likely you are to mitigate the serious consequences of drug-resistant epilepsy (DRE) with focal onset. The VNS Therapy system is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy™ visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK Reference: Otsuki T, Kim H-D, Luan G, et al. Brain Dev. 2016;38(5):460.

Neuronetics, Inc. has just received FDA clearance for its transcranial magnetic stimulation (TMS) device to treat adolescents with major depressive disorder (#MDD), now covering ages 15 to 21. This clearance follows real-world data showing significant improvements in depression severity for 78% of patients. Analysts at William Blair consider this clearance a positive surprise, particularly given previous FDA denials for therapies in this patient population. This expanded clearance is a significant opportunity for Neuronetics, with CEO Keith Sullivan stating it increases their addressable market in MDD by 35%. The company reported fourth-quarter sales exceeding $20 million, up 12% from last year, and is forecasting up to $80 million in global revenues for this year. With a focus on increasing awareness and education about their expanded label, Neuronetics is also working on reimbursement education to support existing practices and expand coverage. https://lnkd.in/dAq4iCUe #MentalHealth #FDAApproval #HealthTech #HealthcareNews"

Children 4 years and older with uncontrolled seizures could experience developmental limitations that impact cognitive and social function. Poorly controlled seizures have serious cognitive consequences in the developing brain. The sooner you act to control seizures, the more likely you are to mitigate the serious consequences of drug-resistant epilepsy (DRE) with focal onset. The VNS Therapy system is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy™ visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK Reference: Otsuki T, Kim H-D, Luan G, et al. Brain Dev. 2016;38(5):460.